Vera Therapeutics
VERA· Manufacturing· Fiscal year ends in December
Marshall Fordyce, M.D. is the CEO of Vera Therapeutics and was paid $7.0M in FY2025 (Dec), up 24%.
Executives5
See all- 1Marshall Fordyce, M.D.President and Chief Executive OfficerFY2025
- 2David Johnson, M.B.A.Chief Operating OfficerFY2025
- 3Robert Brenner, M.D.Chief Medical OfficerFY2025
- 4Sean GrantChief Financial OfficerFY2025
- 5William TurnerChief Regulatory OfficerFY2025
Named executives and their total pay, from the Summary Compensation Table of the latest proxy.
Pay
See allVera Therapeutics paid its 5 named executives $17.5M in total in FY2025 (Dec). CEO Marshall Fordyce, M.D. was paid $7.0M of that.
| Name | |||
|---|---|---|---|
| Marshall Fordyce, M.D.President and Chief Executive Officer | |||
| David Johnson, M.B.A.Chief Operating Officer | |||
| Robert Brenner, M.D.Chief Medical Officer | Not disclosed | ||
| Sean GrantChief Financial Officer | |||
| William TurnerChief Regulatory Officer |
of each named executive, from the Summary Compensation Table of each proxy.
Peers18
See allThe FY2025 (Dec) proxy of Vera Therapeutics names 18 peer companies for pay. Among Vera Therapeutics and these peers, CEO pay was 7th highest of 9 and total shareholder return was 4th highest of 9.
7th highest of 9in Vera Therapeutics and its pay peers, FY2025 (Dec) by CEO pay:
4th highest of 9in Vera Therapeutics and its pay peers, FY2025 (Dec) by total shareholder return:
The comes from the company's proxy. CEO pay and of each company come from its own Pay versus Performance table for the same fiscal year.
Activity
Filings6
See all| Proxy statement | DEF 14A | Apr 9, 2026 | FY2025 |
| Annual report | 10-K | Feb 26, 2026 | FY2025 |
| Proxy statement | DEF 14A | Apr 3, 2025 | FY2024 |
| Annual report | 10-K | Feb 28, 2025 | FY2024 |
| Proxy statement | DEF 14A | Apr 3, 2024 | FY2023 |
| Annual report | 10-K | Mar 27, 2024 | FY2023 |
